PINEAPPLE EXPRESS CANNABIS CO - Form 10-K SEC filing

 0001710495 --01-31 false 2025 FY

 2024-07-31

 2025-05-15

 2023-02-01

 2023-01-31

 2023-01-31

 2023-01-31

 2023-01-31

 2023-02-01

 2023-02-01

 2023-02-01

 fil: GroovyCompanyMember

 2025-02-01
 2025-05-14

 2025-02-01
 2025-05-14

 2025-01-30

 fil: PciEquipmentCarryingValueMember

 fil: PciIntangibleAssetCarryingValueMember

 fil: PciOutstandingNotesPayableMember

 fil: PciAccountsPayableAndAccruedLiabilitiesMember

 fil: GroovyCompanyMember

 2025-03-05

 2025-03-01
 2025-03-31

 2025-05-01
 2025-05-14

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C.

 FORM 10-K

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the Fiscal Year Ended January 31, 2025

 OR

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 Commission File Number 001-41762

 PINEAPPLE EXPRESS CANNABIS CO MPANY

 ( Exact name of registrant as specified in its charter)

 Nevada

 33-3266062

 ( State of incorporation or organization)

 ( IRS Employer Identification No.)

 300 Peachtree St. NE, Ste #1775

 Atlanta, GA 30308 -3565

 ( Address of Principal Executive Offices) ( Zip Code)

 1- 404 - 734-3277

 ( Registrant's telephone number, including area code)

 Email: info@pinya.work

 Communication Copies to

 Jeff Turner

 JDT Legal

 897 W Baxter Dr.

 South Jordan, Utah 84095

 Phone: 801.810.4465

 Fax: 888.920.1297

 jeff@jdt-legal.com

 Securities to be Registered Under Section 12(g) of the Act:

 Common Stock, Par Value $0.00001

 (Title of Class)

 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 i

 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

 Indicate by check mark whether the registrant (1) has filed all reports to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K

 Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large, accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

 Large, accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes No

 On July 31, 2024, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the registrant's common stock held by non-affiliates of the registrant was approximately $ 0, based upon the closing price on that date of the common stock of the registrant on the OTC Link alternative quotation system of $0.00. For purposes of this response, the registrant has assumed that its directors, executive officers and beneficial owners of 5% or more of its common stock are deemed to be affiliates of the registrant.

 As of May 15, 2025, the Company had 21,334,550 outstanding shares of common stock.

 Documents incorporated by reference: None.

 ii

 ANNUAL REPORT ON FORM 10-K

 Fiscal Year Ended January 31, 2025

 Special Note Regarding Forward Looking Statements

 Item 1.

 Description of Business

 Item 1A.

 Risk Factors

 Item 1B.

 Unresolved Staff Comments

 Item 2.

 Description of Property

 Item 3.

 Legal Proceedings

 Item 4.

 Mine Safety Disclosures

 Item 5.

 Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchase of Equity Securities

 Item 6.

 Selected Financial Data

 Item 7.

 Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 7A.

 Quantitative and Qualitative Disclosure About Market Risk

 Item 8.

 Financial Statements and Supplementary Data

 Item 9.

 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 Item 9A.

 Controls and Procedures

 Item 9B.

 Other Information

 Item 9C.

 Disclosure Regarding Foreign Juristriction that Prevents Inspections

 Item 10.

 Directors, Executive Officers and Corporate Governance

 Item 11.

 Executive Compensation

 Item 12.

 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13.

 Certain Relationships and Related Transactions, and Director Independence

 Item 14.

 Principal Accountant Fees and Services

 Item 15.

 Exhibits, Financial Statement Schedule

 Signatures

 iii

 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements reflect management's current expectations, assumptions, and projections about future events or financial performance and are not guarantees of future results. Forward-looking statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Statements containing words like "believe," "anticipate," "endeavor," "estimate," "expect," "project," "intend," or similar expressions identify these forward-looking statements. Specifically, statements regarding future growth, market adoption, regulatory developments, technological advancements, and financial performance are subject to these risks and uncertainties

 Factors that could cause actual results to differ materially from those currently anticipated include, but are not limited to: the risks associated with the evolving cannabis market, including but not limited to regulatory uncertainties and changes in laws and regulations; competitive pressures within the cannabis sector; technological disruptions impacting operational efficiency; fluctuations in market demand; variations in product pricing; the ability to effectively penetrate new markets; and the potential financial or reputational impacts from legal, administrative, or regulatory developments. Further, risks relating to the volatile nature of the cryptocurrency market, potential security breaches, fluctuations in token values, and changes in investor sentiment are relevant considerations. These factors, as well as risks relating to the general economy, market volatility, and competitive activity, are further detailed within the "Risk Factors" section of this document.

 The Company does not undertake any obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events, or otherwise. Investors should carefully consider these factors and the risks discussed throughout this report before making any investment decisions. This statement is made for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Further, investors should independently research and evaluate the potential risks and rewards of investing in the Company and the cannabis and cryptocurrency sectors.

 Use of Market and Industry Data

 This Annual Report on Form 10-K for the fiscal year ended January 31, 2025 (this "Annual Report") includes market and industry data that we have obtained from third-party sources, including industry publications, as well as industry data prepared by our management on the basis of its knowledge of and experience in the industries in which we operate (including our management's estimates and assumptions relating to such industries based on that knowledge). Management has developed its knowledge of such industries through its experience and participation in these industries. While our management believes the third-party sources referred to in this Annual Report are reliable, neither we nor our management have independently verified any of the data from such sources referred to in this Annual Report or ascertained the underlying economic assumptions relied upon by such sources. Furthermore, references in this Annual Report to any publications, reports, surveys, or articles prepared by third parties should not be construed as depicting the complete findings of the entire publication, report, survey, or article. The information in any such publication, report, survey, or article is not incorporated by reference in this Annual Report.

 Forecasts and other forward-looking information obtained from these sources involve risks and uncertainties and are subject to change based on various factors, including those discussed in sections entitled "Forward-Looking Statements," "Item 1A. Risk Factors" and "Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Annual Report.

 Trademarks, Service Marks and Trade Names

 This Annual Report contains references to our trademarks, service marks and trade names and to trademarks, service marks and trade names belonging to other entities. Solely for convenience, trademarks, service marks and trade names referred to in this Annual Report, including logos, artwork, and other visual displays, may appear without the or TM symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies' trade names, service marks or trademarks or any artists' or other individuals' names to imply a relationship with, or endorsement or sponsorship of us by, any other companies or persons.

 Item 1. Description of Business.

 This Annual Report (including, but not limited to, the following disclosures regarding our Business) contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters such as the development of new products, enhancements or technologies, sales levels, expense levels and other statements regarding matters that are not historical are forward-looking statements.

 Forward-looking statements in this Annual Report reflect our good faith judgment based on facts and factors currently known to us. Forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

 Corporate History

 The Company was incorporated as "Minaro Corp." under the laws of the State of Nevada on March 14, 2017.

 On December 18, 2022, Minaro Corp., a Nevada corporation (the "Company"), Yulia Lazaridou, the majority shareholder of the Company ("Lazaridou"), Pineapple Consolidated, Inc., a California corporation ("PCI") and the shareholders of PCI ("PCI Shareholders"), entered into a Share Exchange Agreement (the "Exchange Agreement"). Pursuant to the Exchange Agreement, the PCI Shareholders exchanged (the "Exchange Transaction") 50,000 outstanding shares of common stock of PCI, representing fifty percent (50%) of the outstanding shares of PCI common stock, for eighteen million (18,000,000) newly issued shares of Minaro common stock.

 In addition, on December 18, 2022, in a transaction related to and a condition to the Exchange Transaction, Lazaridou and the Company entered into that certain Resignation, Separation and Release Agreement (the "Resignation Agreement"), pursuant to which (a) the Company redeemed 2,800,000 shares of Company common stock owned by Lazaridou (the "Lazaridou Shares') in exchange for a payment by the Company of $540,904 and (b) Lazaridou, as of December 21, 2022, resigned as the sole director, officer and employee of the Company.

 In order to fund the payment for the Lazaridou Shares, contemporaneous with the Exchange, on December 18, 2022, PCI loaned $540,904 to the Company. The loan (the "PCI Loan") matured on June 30, 2023 and earns interest at an annual rate of 1%.

 In addition, on December 18, 2022, Lazaridou, as sole director and majority shareholder, executed a written consent in lieu of a meeting providing that (i) Matthew Feinstein be elected as the sole director of the Company as well as Chief Executive Officer, President, Secretary, Chairman of the Board and Interim Chief Financial Officer, (ii) accepted the resignation of Lazaridou and (iii) approved the Exchange Agreement and Resignation Agreement. As a result of these transactions, the PCI Shareholders own a majority of the shares of Minaro common stock, and the Company owns fifty percent (50%) of the PCI common stock.

 On January 5, 2023, the Company filed Restated Articles of Incorporation with the State of Nevada following approval of the sole director and majority shareholder ("Restated Articles"). The Restated Articles (i) changed the name of the Company to Pineapple Express Cannabis Company, (ii) added an additional authorized class of capital stock, namely ten million (10,000,000) shares of Preferred Stock, in addition to the previously authorized seventy-five million (75,000,000) shares of Common Stock. As a result, the name of the Company now has been changed to Pineapple Express Cannabis Company.

 On December 30, 2022 the Company applied to the Financial Industry Regulatory Authority ("FINRA") for approval with respect to the change of the Company's name in the Restated Articles. The Company separately applied to FINRA to change the Company's stock ticker trading symbol. These two corporate actions were subject to FINRA review and clearance which was received during this reporting period.

 Business Operations

 Pineapple Express Cannabis Company is based in Los Angeles, California. Pineapple Express Cannabis Company is a Nevada corporation focused on strategic investments, advisory services, and direct operations in the legal cannabis and consumer product industries. Our business model includes identifying and developing early-stage companies that operate in these sectors, providing both capital and operational guidance.

 Until January 2025, our principal operating asset was a 50% equity interest in Pineapple Consolidated Inc. ("PCI"), a California-based cannabis retail operator. PCI operated through multiple subsidiaries and affiliates in the legal cannabis sector, primarily in California. Through our affiliation with PCI, we participated indirectly in the ownership and management of retail dispensary operations and related cannabis ventures. However, on January 30, 2025, we divested our entire equity interest in PCI, thereby concluding our investment in cannabis retail operations.

 On March 5, 2025, subsequent to the end of the fiscal year, the Company completed the acquisition of a majority voting interest in GROOVY Company, Inc. ("GROOVY"), a Wyoming corporation and developer of a centralized, blockchain-based Platform as a Service (PaaS) tailored for the cannabis industry. GROOVY's platform, built on Hyperledger Fabric, delivers product authentication, intellectual property protection, and seed-to-sale traceability solutions.

 Key features of the GROOVY platform include:

 NFT-based QR code authentication to detect and prevent product counterfeiting

 A genetic library (Geno-NFT) for intellectual property registration and automated royalty distribution

 Verified product provenance and lab result tracking

 A consumer-facing mobile app offering rewards-based engagement

 Integration with inventory, compliance, and supply chain systems used by growers, retailers, and regulators

 A data analytics and marketplace environment for ecosystem-wide insights

 This strategic acquisition marks the Company's entry into blockchain-driven authentication and supply chain transparency for the regulated cannabis sector, positioning it at the intersection of cannabis, compliance technology, and Web3 infrastructure.

 Principal executive office

 Our principal executive office is located at 300 Peachtree St. NE Ste CS2 #1775 Atlanta, GA 30308-3565. This property is leased by management and to the Company. We believe these facilities are adequate for our current needs, and that alternate facilities on similar terms would be readily available, if needed. The principal executive offices lease is due on March 31, 2026. The Company does not have any additional subsidiary office.

 Operational office

 Operations Office located at V a Siberia, Autopista Medell n, Bogot -La Vega #Km. 3,5, Cota, Cundinamarca, Colombia. The company's newly short term leased office space in Bogot, Colombia, is approximately 350 square feet. This smaller space accommodates a team of 3-6 employees and/or contractors and shares common areas like a kitchen and restrooms with other tenants. The revised facilities reflect the company's adjusted staffing levels and its shift toward a more flexible work model, including remote work options..

 Research And Development Expenditures

 We have not incurred any research expenditures since our incorporation.

 Bankruptcy Or Similar Proceedings

 There has been no bankruptcy, receivership or similar proceeding entered into either voluntarily by the Company and involuntarily against the Company.

 Compliance With Government Regulation

 We are required to comply with all regulations, rules and directives of governmental authorities and agencies applicable to the construction and operation of any facility in any jurisdiction which we would conduct activities.

 We do not believe that any existing or probable government regulation on our business will have a material impact on the way we conduct our business.

 Employees And Employment Agreements

 We have no employees as of the date of this report. Our sole officer and director, Franjose "Frank" Yglesias, currently devotes as much time as needed to provide management services to company matters. As our business and operations increase, we will assess the need for full-time management and administrative support personnel.

 Regulatory Overview

 As of the date of this filing, 40 states and four (4) territories allow for the medical use of cannabis products, while 17 of those states, the District of Columbia, the Northern Mariana Islands, and Guam have also legalized the adult-use of cannabis. Although legalized in some states, cannabis is a "Schedule 1" drug under the Controlled Substances Act (21 U.S.C. § 811) ("CSA") and is illegal under federal law.

 On August 29, 2013, the Department of Justice set out its prosecutorial priorities in light of various states legalizing cannabis for medicinal and/or recreational use. The "Cole Memorandum" provided that when states have implemented strong and effective regulatory and enforcement systems to control the cultivation, distribution, sale, and possession of cannabis, conduct in compliance with those laws and regulations is less likely to threaten the federal priorities. Indeed, a robust system may affirmatively address those priorities by, for example, implementing effective measures to prevent diversion of cannabis outside of the regulated system and to other states, prohibiting access to cannabis by minors, and replacing an illicit cannabis trade that funds criminal enterprises with a tightly regulated market in which revenues are tracked and accounted for. In those circumstances, consistent with the traditional allocation of federal-state efforts in this area, the Cole Memorandum provided that enforcement of state law by state and local law enforcement and regulatory bodies should remain the primary means of addressing cannabis-related activity. If state enforcement efforts are not sufficiently robust to protect against the harms set forth above, the federal government may seek to challenge the regulatory structure itself in addition to continuing to bring individual enforcement actions, including criminal prosecutions, focused on those harms.

 On January 4, 2018, Attorney General Jeff Sessions issued a memorandum for all United States Attorneys concerning cannabis enforcement under the Controlled Substances Act (CSA). Mr. Sessions rescinded all previous prosecutorial guidance issued by the Department of Justice regarding cannabis, including the August 29, 2013 "Cole Memorandum".

 In rescinding the Cole Memorandum, Mr. Sessions stated that U.S. Attorneys must decide whether or not to pursue prosecution of cannabis activity based upon factors including: the seriousness of the crime, the deterrent effect of criminal prosecution, and the cumulative impact of particular crimes on the community. Mr. Sessions reiterated that the cultivation, distribution, and possession of marijuana continues to be a crime under the U.S. Controlled Substances Act.

 On March 23, 2018, President Donald J. Trump signed into law a $1.3 trillion-dollar spending bill that included an amendment known as "Rohrabacher-Blumenauer," which prohibits the Justice Department from using federal funds to prevent certain states "from implementing their own State laws that authorize the use, distribution, possession or cultivation of medical cannabis."

 On December 20, 2018, President Donald J. Trump signed into law the Agriculture Improvement Act of 2018, otherwise known as the "Farm Bill". Prior to its passage, hemp, a member of the cannabis family, was classified as a Schedule 1 controlled substance, and so illegal under the federal CSA.

 With the passage of the Farm Bill, hemp cultivation is now broadly permitted. The Farm Bill explicitly allows the transfer of hemp-derived products across state lines for commercial or other purposes. It also puts no restrictions on the sale, transport, or possession of hemp-derived products, so long as those items are produced in a manner consistent with the law.

 Under Section 10113 of the Farm Bill, hemp cannot contain more than 0.3 percent THC. THC refers to the chemical compound found in cannabis that produces the psychoactive "high" associated with cannabis. Any cannabis plant that contains more than 0.3 percent THC would be considered non-hemp cannabis-or marijuana-under the CSA and would not be legally protected under this new legislation and would be treated as an illegal Schedule 1 drug.

 Additionally, there will be significant, shared state-federal regulatory power over hemp cultivation and production. Under Section 10113 of the Farm Bill, state departments of agriculture must consult with the state's governor and chief law enforcement officer to devise a plan that must be submitted to the Secretary of the United States Department of Agriculture (hereafter referred to as the "USDA"). A state's plan to license and regulate hemp can only commence once the Secretary of USDA approves that state's plan. In states opting not to devise a hemp regulatory program, USDA will construct a regulatory program under which hemp cultivators in those states must apply for licenses and comply with a federally run program. This system of shared regulatory programming is similar to options states had in other policy areas, such as health insurance marketplaces under the Affordable Care Act, or workplace safety plans under the Occupational Health and Safety Act-both of which had federally-run systems for states opting not to set up their own systems.

 The Farm Bill outlines actions that are considered violations of federal hemp law (including such activities as cultivating without a license or producing cannabis with more than 0.3 percent THC). The Farm Bill details possible punishments for such violations, pathways for violators to become compliant, and even which activities qualify as felonies under the law, such as repeated offenses.

 One of the goals of the previous 2014 Farm Bill was to generate and protect research into hemp. The 2018 Farm Bill continues this effort. Section 7605 re-extends the protections for hemp research and the conditions under which such research can and should be conducted. Further, section 7501 of the Farm Bill extends hemp research by including hemp under the Critical Agricultural Materials Act. This provision recognizes the importance, diversity, and opportunity of the plant and the products that can be derived from it, but also recognizes that there is a still a lot to learn about hemp and its products from commercial and market perspectives.

 On January 21, 2021, Joseph R. Biden, Jr. was sworn in as President of the United States. President Biden's Attorney General, Merrick Garland, was confirmed by the United States Senate on March 10, 2021. It is not yet known whether the Department of Justice ("DOJ"), under President Biden and Attorney General Garland, will re-adopt the Cole Memorandum or announce a substantive marijuana enforcement policy. During his Senate confirmation, Merrick Garland told Senator Cory Booker (D-NJ), "It does not seem to me useful the use of limited resources that we have to be pursuing prosecutions in states that have legalized and are regulating the use of marijuana, either medically or otherwise." Such statements are not official declarations or policies of the DOJ and are not binding on the DOJ, any United States Attorney, or the United States federal courts. Substantial uncertainty regarding United States federal enforcement remains. To date, there have been no new federal cannabis memorandums issued by the Biden Administration or any published change in federal enforcement policy.

 On January 20, 2025, Donald J. Trump was sworn in as President of the United States for his second term. President Trump's Attorney General, Pam Bondi, was confirmed by the United States Senate on February 4, 2025. To date, the Department of Justice ("DOJ"), under President Trump and Attorney General Bondi, has not re-adopted the Cole Memorandum, which was previously rescinded during Trump's first term by then-Attorney General Jeff Sessions in January 2018. While President Trump has expressed support for states' rights regarding cannabis legalization and indicated potential backing for federal rescheduling of marijuana during his campaign, his administration has not yet issued any official declarations or comprehensive marijuana enforcement policies. Attorney General Bondi, who

 previously opposed cannabis legalization efforts during her tenure as Florida's Attorney General, has not made specific public statements regarding federal cannabis enforcement priorities since taking office. Substantial uncertainty regarding United States federal enforcement therefore remains. At this time, there have been no new federal cannabis memorandums issued by the Trump Administration or any published change in federal enforcement policy.

 As of May 2025, 41 states, the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands, and the U.S. Virgin Islands have legalized some form of medical cannabis use, while 24 states, the District of Columbia, Guam, the Northern Mariana Islands, and the U.S. Virgin Islands have also legalized adult-use (recreational) cannabis. There can be no assurance that the number of states allowing the use of medicinal and recreational cannabis will continue to grow, and there exists the possibility that states may reverse their positions and make medicinal and recreational cannabis illegal again. If either of these scenarios occurs, not only will the growth of our business be materially impacted, but we may experience declining revenue as the market for our products and services contracts.

 Since 2020, several states have newly legalized recreational (adult-use) marijuana, including Arizona, Montana, New Jersey, New York, Virginia, Connecticut, New Mexico, Maryland, Minnesota, Ohio, and Delaware. Additionally, Mississippi and Alabama have established medical marijuana programs in recent years. The U.S. Virgin Islands legalized recreational use in January 2023, joining the growing number of U.S. territories with comprehensive cannabis reform.

 The Investment Company Act contains substantive legal requirements that regulate the manner in which "investment companies" are permitted to conduct their business activities. We believe that we have conducted our business in a manner that does not result in being characterized as an "investment company" under the Investment Company Act because we are primarily engaged in a non-investment company business. Although a portion of our assets may constitute investments in non-controlled entities, we believe that we are not an investment company as defined by the Investment Company Act. While we intend to conduct our operations such that we will not be deemed an investment company, such a determination would require us to initiate burdensome compliance requirements and comply with restrictions imposed by the Investment Company Act that would limit our activities, including limitations on our capital structure and our ability to transact with affiliates, which would have an adverse effect on our financial condition. To avoid such a determination, we may be required to conduct our business in a manner that does not subject us to the requirements of the Investment Company Act, which could have an adverse effect on our business. For example, we may be required to sell certain of our assets and pay significant taxes upon the sale or transfer of such assets

 Recent Developments

 Sale of Pineapple Consolidated Inc. (PCI)

 On January 31, 2025, the Company entered into a Stock Purchase Agreement with Matthew Feinstein, who at the time was the Company's President, Chief Executive Officer, Treasurer, and Director. Pursuant to the agreement, the Company sold its remaining ownership interest in Pineapple Consolidated, Inc. ("PCI") to Mr. Feinstein in exchange for a $3,000,000 reduction in the outstanding principal amount of a promissory note previously issued by PCI to the Company. As a result of the transaction, the Company no longer retains any ownership interest in PCI. The decision to divest our interest in PCI was part of a broader strategic shift to reduce regulatory exposure associated with direct participation in cannabis operations and to reposition the Company toward technology and consumer-facing ventures. The Company recorded a loss on the disposition of PCI of $14,296 during the fiscal year ended January 31, 2025.

 Acquisition of Majority Interest in GROOVY Corporation

 On March 5, 2025, subsequent to the end of the fiscal year, the Company completed the acquisition of a majority voting interest in GROOVY Company, Inc. ("GROOVY"), a Wyoming corporation and developer of a centralized, blockchain-based Platform as a Service (PaaS) tailored for the cannabis industry. GROOVY's platform, built on Hyperledger Fabric, delivers product authentication, intellectual property protection, and seed-to-sale traceability solutions.

 Key features of the GROOVY platform include:

 NFT-based QR code authentication to detect and prevent product counterfeiting

 A genetic library (Geno-NFT) for intellectual property registration and automated royalty distribution

 Verified product provenance and lab result tracking

 A consumer-facing mobile app offering rewards-based engagement

 Integration with inventory, compliance, and supply chain systems used by growers, retailers, and regulators

 A data analytics and marketplace environment for ecosystem-wide insights

 This strategic acquisition marks the Company's entry into blockchain-driven authentication and supply chain transparency for the regulated cannabis sector, positioning it at the intersection of cannabis, compliance technology, and Web3 infrastructure.

 Item 1A. Risk Factors.

 Risks Related to Our Company and Our Business

 We have a limited operating history and operate in a new industry, and we may not succeed.

 We have a limited operating history and may not succeed. We are subject to all risks inherent in a developing business enterprise. Our likelihood of continued success must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with manufacturing specialty products and the competitive and regulatory environment in which we operate. For example, the cannabis industry is a new industry that may not succeed, particularly should the Federal government change course and decide to prosecute those dealing in medical or recreational cannabis. In such event, there may not be an adequate market for our products. As a new industry, there are few established players whose business models we can follow. Similarly, there is little information about comparable companies for potential investors to review in making a decision about whether to invest in the Company.

 Potential investors should consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by companies that, like us, are in their early stages. For example, unanticipated expenses, unexpected problems, and technical difficulties may occur and they may result in material delays in the operation of our business, in particular with respect to our new products. We may not successfully address these risks and uncertainties or successfully implement our operating strategies. If we fail to do so, it could materially harm our business to the point of having to cease operations and could impair the value of our Common Stock to the point investors may lose their entire investment.

 Uncertainty of profitability.

 Our business strategy may result in increased volatility of revenues and earnings. As we will only develop a limited number of products and services at a time, our overall success will depend on a limited number of products and services, which may cause variability and unsteady profits and losses depending on the products and services offered and their market acceptance.

 Our revenues and our profitability may be adversely affected by economic conditions and changes in the market for medical and recreational marijuana. Our business is also subject to general economic risks that could adversely impact the results of operations and financial condition.

 Because of the anticipated nature of the products and services that we offer and attempt to develop, it is difficult to accurately forecast revenues and operating results and these items could fluctuate in the future due to a number of factors. These factors may include, among other things, the following:

 Our ability to raise sufficient capital to take advantage of opportunities and generate sufficient revenues to cover expenses.

 Our ability to source strong opportunities with sufficient risk adjusted returns.

 Our ability to manage our capital and liquidity requirements based on changing market conditions generally and changes in the developing legal medical marijuana and recreational marijuana industries.

 The acceptance of the terms and conditions of our services.

 The amount and timing of operating and other costs and expenses.

 The nature and extent of competition from other companies that may reduce market share and create pressure on pricing and investment return expectations.

 Adverse changes in the national and regional economies in which we will participate, including, but not limited to, changes in our performance, capital availability, and market demand.

 Adverse changes in the projects in which we plan to invest, which result from factors beyond our control, including, but not limited to, a change in circumstances, capacity and economic impacts.

 Adverse developments in the efforts to legalize marijuana or increased federal enforcement.

 Changes in laws, regulations, accounting, taxation, and other requirements affecting our operations and business.

 Our operating results may fluctuate from year to year due to the factors listed above and others not listed. At times, these fluctuations may be significant.

 Cannabis remains illegal under federal law.

 Cannabis is a categorized as a Schedule I controlled substance by the Drug Enforcement Agency and the United States Department of Justice and is illegal to grow, possess and consume under federal law. Even in those jurisdictions in which the use of medical cannabis has been legalized at the state level, its use remains a violation of federal law. The United States Supreme Court has ruled in United States v. Oakland Cannabis Buyers' Coop. and Gonzales v. Raich that it is the federal government that has the right to regulate and criminalize cannabis, even for medical purposes. Therefore, federal law criminalizing the use of cannabis preempts state laws that legalize its use for medicinal or adult-retail purposes. Strict enforcement of federal law regarding cannabis would likely result in our inability to proceed with our business plan.

 The previous Obama administration has effectively stated that it is not an efficient use of resources to direct federal law enforcement agencies to prosecute those lawfully abiding by state-designated laws allowing the use and distribution of medical cannabis. In furtherance thereof, on August 29, 2013, the Department of Justice provided guidance to all U.S. federal prosecutors with respect to the enforcement of laws regarding cannabis via the publication of a memorandum authored by former US Attorney General James M. Cole (the "Cole Memo"). The Cole Memo stated that enforcement should be focused on eight priorities, which is to prevent: (1) distribution of cannabis to minors; (2) revenue from sale of cannabis to criminal enterprises, gangs and cartels; (3) transfer of cannabis from states where it is legal to states where it is illegal; (4) cannabis activity from being a pretext for trafficking of other illegal drugs or illegal activity; (5) violence of use of firearms in cannabis growth and distribution; (6) drugged driving and adverse public health consequences from cannabis use; (7) growth of cannabis on federal lands; and (8) cannabis possession or use on federal property.

 On January 4, 2017, the U.S. Attorney General Jeff Sessions rescinded the Cole Memo and restored the "rule of law." Such rescission essentially shifts federal policy from the hands-off approach adopted under the Obama administration to allowing federal prosecutors across the U.S. to decide individually how to prioritize resources to crack down on pot possession, distribution and cultivation of the drug in states where it is legal. Furthermore, the Trump administration has previously indicated that it will pursue the enforcement of federal cannabis laws.

 While we do not believe our current activities involve those enumerated in the Cole Memo, in light of the rescission of the memo by the current Attorney General, federal prosecutors will now have significant discretion on their interpretation of these priorities, and no assurances can be given that federal prosecutors will agree with our position. We therefore cannot provide assurance that our actions are in full compliance with the Cole Memo or any other state or federal laws or regulations. In addition, there is no guarantee that the current administration will not further change its policy regarding the strict enforcement of federal laws or the eight listed priorities. Additionally, any new administration that follows could change this policy and decide to enforce the federal laws even stronger. Any such change in the federal government's enforcement of current federal laws could cause significant financial damage to us and our shareholders.

 The cannabis industry faces strong opposition.

 It is believed by many that large well-funded businesses may have a strong economic opposition to the cannabis industry. We believe that the pharmaceutical industry does not want to cede control of any product that could generate significant revenue. For example, medical cannabis will likely adversely impact the existing market for medicines sold by mainstream pharmaceutical companies that contain active ingredients from cannabis. Furthermore, the medical marijuana industry could face a material threat from the pharmaceutical industry, should marijuana displace other drugs or encroach upon the pharmaceutical industry's products. The pharmaceutical industry is well funded with a strong and experienced lobby that eclipses the funding of the medical cannabis movement. Any inroads the pharmaceutical industry could make in halting or impeding the cannabis industry could have a detrimental impact on our proposed business.

 Additionally, we are substantially dependent on continued market acceptance and proliferation of consumers of cannabis, medical marijuana, and recreational marijuana. We believe that as marijuana becomes more accepted the stigma associated with marijuana use will diminish and as a result consumer demand will continue to grow. While we believe that the market and opportunity in the marijuana space continues to grow, we cannot predict the future growth rate and size of the market. Any negative outlook on the marijuana industry will adversely affect our business operations.

 There is uncertainty regarding the availability of U.S. federal patent and trademark protection.

 As long as cannabis remains illegal under U.S. federal law, the benefit of certain federal laws and protections which may be available to most businesses, such as federal trademark and patent protection regarding the intellectual property of a business, may not be available to us. As a result, our intellectual property may never be adequately or sufficiently protected against the use or misappropriation by third parties. In addition, since the regulatory framework of the cannabis industry is in a constant state of flux, we can provide no assurance that it will ever obtain any protection of its intellectual property, whether on a federal, state, or local level.

 There may be a U.S. Food and Drug Administration ("FDA") risk.

 If legalization occurs federally, the FDA could impose additional regulations or risks on cannabis.

 We could experience difficulty enforcing our contracts.

 Due to the nature of our business and the fact that our equity method investee, Pineapple Consolidated, Inc. contracts involve cannabis and other activities that are not legal under U.S. federal law and in some jurisdictions, we may face difficulties in enforcing our contracts in federal and certain state courts. The inability to enforce any of our contracts could have a material adverse effect on our business, operating results, financial condition, or prospects.

 We and our customers and clients may have difficulty accessing the service of banks, which may make it difficult for them to operate.

 Since the use of cannabis is illegal under federal law, there is a compelling argument that banks cannot accept for deposit funds from businesses involved with cannabis. While the Financial Crimes Enforcement Network ("FinCEN") has provided guidance to financial institutions on how to provide services to marijuana-related businesses consistent with their Bank Secrecy Act obligations, the decision to open, close, or refuse accounts and/or relationships are made at the discretion of the banking institution. Consequently, businesses involved in the cannabis industry often have trouble finding a bank willing to accept their business. The inability to open bank accounts may make it difficult for us and our clients to operate.

 Due to our ancillary involvement in the cannabis industry, we may have a difficult time obtaining the various insurances that are desired to operate our business, which may expose us to additional risk and financial liability.

 Insurance that is otherwise readily available, such as general liability, and directors and officer's insurance, is more difficult for us to find, and more expensive, because we are service providers to companies in the cannabis industry. There are no guarantees that we will be able to find such insurances in the future, or that the cost will be affordable to

 us. If we are forced to go without such insurances, it may prevent us from entering into certain business sectors, may inhibit our growth, and may expose us to additional risk and financial liabilities.

 The cannabis industry is relatively new.

 We are operating in a relatively new industry and market. In addition to being subject to general business risks, we must continue to build brand awareness in this industry and market share through significant investments in our strategy, production capacity, quality assurance and compliance with regulations. Research in the United States and internationally regarding the medical benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids, such as cannabidiol, or CBD, and tetrahydrocannabinol, or THC, remains in relatively early stages. Few clinical trials on the benefits of cannabis or isolated cannabinoids have been conducted. Future research and clinical trials may draw opposing conclusions to statements contained in the articles, reports and studies currently favored, or could reach different or negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing or other facts and perceptions related to medical cannabis, which could adversely affect social acceptance of cannabis and the demand for our products and dispensary services.

 Accordingly, there is no assurance that the cannabis industry and the market for medicinal and/or adult-use cannabis will continue to exist and grow as currently anticipated or function and evolve in a manner consistent with management's expectations and assumptions. Any event or circumstance that adversely affects the cannabis industry, such as the imposition of further restrictions on sales and marketing or further restrictions on sales in certain areas and markets could have a material adverse effect on our business, financial condition, and results of operations.

 We face risks due to industry immaturity or limited comparable, competitive, or established industry best practices.

 As a relatively new industry, there are not many established operators in the medical and adult use cannabis industries whose business models we can follow or build upon. Similarly, there is no or limited information about comparable companies available for potential investors to review in making a decision about whether to invest in us.

 Shareholders and investors should consider, among other factors, our prospects for success in light of the risks and uncertainties encountered by companies, like us, that are in their early stages. For example, unanticipated expenses and problems or technical difficulties may occur, which may result in material delays in the operation of our business. We may fail to successfully address these risks and uncertainties or successfully implement our operating strategies. If we fail to do so, it could materially harm our business to the point of having to cease operations and could impair the value of the Subordinate Voting Shares to the extent that investors may lose their entire investments.

 Our ability to grow our medical and adult-use cannabis product offerings and dispensary services may be limited.

 As we introduce or expand our medical and adult-use cannabis product offerings and dispensary services, we may incur losses or otherwise fail to enter certain markets successfully. Our expansion into new markets may place us in competitive and regulatory environments with which we are unfamiliar and involve various risks, including the need to invest significant resources and the possibility that returns on those investments will not be achieved for several years, if at all. In attempting to establish new product offerings or dispensary services, we may incur significant expenses and face various other challenges, such as expanding our work force and management personnel to cover these markets and complying with complicated cannabis regulations that apply to these markets. In addition, we may not successfully demonstrate the value of these product offerings and dispensary services to consumers, and failure to do so would compromise our ability to successfully expand these additional revenue streams.

 Laws and regulations affecting the cannabis industry are constantly changing, which could detrimentally affect our business, and we cannot predict the impact that future regulations may have on us.

 Local, state and federal medical cannabis laws and regulations are broad in scope, and they are subject to evolving interpretations, which could require our licensees to incur substantial costs associated with compliance or to alter one or more of their sales or marketing practices. For example, the rescission of the Cole Memo by U.S. Attorney General Jeff Sessions on January 4, 2018. In addition, violations of these laws, or allegations of such violations, could disrupt our license business and result in a material adverse effect on our revenues under our license agreements, which would negatively affect our profitability and financial condition.

 In addition, it is possible that regulations may be enacted in the future that will be directly applicable to us and our business. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative policies and procedures, when and if promulgated, could have on our business. These potential effects could include, however, requirements for the revisions to our business model to meet new standards, the recall or discontinuance of certain products, or additional record keeping and reporting requirements. Any or all of these requirements could have a material adverse effect on our business, financial condition, and results of operations.

 We are subject to complex laws and regulations, including environmental laws and regulations, which can adversely affect the cost, manner and feasibility of doing business.

 We are subject to complex laws and regulations, including environmental laws and regulations, which can adversely affect the cost, manner and feasibility of doing business. The operations and facilities of our facilities will be subject to extensive federal, state, and local laws and regulations relating to the growth of cannabis and the manufacture and distribution of products containing cannabis (and/or its psychoactive compound, THC). Such existing laws or regulations regarding cannabis and its psychoactive compound, as currently interpreted or reinterpreted in the future, or future laws or regulations, may adversely affect our businesses and sales. Consequently, our revenues would thereby decrease, which may have a material adverse effect on our results of operations.

 Ordinary and necessary business deduction other than the cost of goods sold are disallowed by the Internal Revenue Service for Cannabis companies under the Internal Revenue Code (the "IRC") Section 280E.

 IRC Section 280E prohibits cannabis businesses from deducting ordinary and necessary business expenses pertaining to cannabis sale, forcing the Company to contend with higher effective federal tax rates than similar companies in other industries. This onerous tax burden significantly impacts the profitability of the cannabis businesses and may make the pricing of its products less competitive.

 If no additional states allow the medicinal or adult-retail use of cannabis, or if one or more states that currently allow it, reverse their position, we may not be able to continue our growth, or the market for our products and services may decline.

 As of January 31, 2024, 40 states and the District of Columbia, the Northern Mariana Islands, Guam and Puerto Rico have passed laws allowing some degree of medical use of cannabis, while eighteen (18) of those states and the District of Columbia, the Northern Mariana Islands, and Guam, have also legalized the adult-use of cannabis. There can be no assurance that number of states that allow the use of medicinal and recreational cannabis will grow, and if it does not, there can be no assurance that the 37 existing states and/or the District of Columbia will not reverse their position and make medicinal and recreational cannabis illegal again. If either of these things happens, then not only will the growth of our business be materially impacted, but we may experience declining revenue as the market for our products and services declines.

 Arizona, Montana, New Jersey, South Dakota, New York, Virginia, Connecticut, and New Mexico passed laws allowing recreational (adult-use) marijuana and Mississippi and Alabama passed an initiative allowing medical marijuana.

 We may not be able to effectively control and manage our growth.

 Our strategy envisions a period of potentially rapid growth. We currently maintain nominal administrative and personnel capacity due to the startup nature of our business, and our expected growth may impose a significant burden on our future planned administrative and operational resources. The growth of our business may require significant investments of capital and increased demands on our management, workforce and facilities. We will be required to substantially expand our administrative and operational resources and attract, train, manage and retain qualified management and other personnel. Failure to do so or satisfy such increased demands would interrupt or would have a material adverse effect on our business and results of operations.

 Our industry is highly competitive, and we have less capital and resources than many of our competitors which may give them an advantage in developing and marketing products similar to ours or make our products obsolete.

 We are involved in a highly competitive industry where we may compete with numerous other companies who offer alternative methods or approaches, who may have far greater resources, more experience, and personnel perhaps more qualified than we do. Such resources may give our competitors an advantage in developing and marketing products similar to ours or products that make our products obsolete. There can be no assurance that we will be able to successfully compete against these other entities.

 The success of our new and existing partnerships, products, and services is uncertain, and large resources may be required to sustain our current business model.

 We have committed, and expect to continue to commit, significant resources and capital to develop and market existing partnership, product, and service enhancements as well as new partnerships, products and services. These partnerships, products and services are relatively new and untested, and we cannot assure you that we will achieve market acceptance for these partnerships, products, and services, or other new partnerships, products and services that we may offer in the future. Moreover, these and other new partnerships, products and services may be subject to significant competition with offerings by new and existing competitors in our sector. In addition, new partnerships, products, services and enhancements may pose a variety of technical challenges and require us to attract additional qualified employees. The failure to successfully develop and market these new partnerships, products, services, or enhancements could seriously harm our business, financial condition and results of operations.

 Our business is dependent upon continued market acceptance by consumers.

 We are substantially dependent on continued market acceptance of our products and our licensees', lessee's, or tenant's products by consumers. Although we believe that the use of cannabis in the United States is gaining stronger consumer acceptance, we cannot predict the future growth rate and size of this market.

 If we fail to successfully introduce new partnerships or products, we may lose market position.

 New partnerships, products, and product improvements, and line extensions will be an important factor in our sales growth. If we fail to identify emerging consumer and technological trends, to maintain and improve the competitiveness of our existing partnerships and products or to successfully introduce new products on a timely basis, we may lose market position. Continued business development, product development, and marketing efforts have all the risks inherent in the development of new partnerships, products, and line extensions, including development delays, the failure of new partnerships, products and line extensions to achieve anticipated levels of market acceptance and the cost of failed product introductions.

 We may be unable to adequately protect or enforce our patents and proprietary rights.

 Our continuing success depends, in part, on our ability to protect our intellectual property and maintain the proprietary nature of our technology through a combination of patents, trademarks, licenses and other intellectual property arrangements, without infringing the proprietary rights of third parties. We cannot assure that these patents, trademarks, licenses and other intellectual property arrangements will be held valid if challenged, or that other parties will not claim rights in or ownership of our patent and other proprietary rights. We also cannot assure that our pending patents will be issued. Moreover, patents issued to us or those we license patents from may be circumvented or fail to provide adequate protection.

 Litigation brought by third parties claiming infringement of their intellectual property rights or trying to invalidate intellectual property rights owned or used by us may be costly and time consuming.

 We may face lawsuits from time to time alleging that our intellectual property infringes on third-party intellectual property, and/or seeking to invalidate or limit our ability to use our intellectual property.

 If we become involved in litigation, we may incur substantial expense defending these claims and the proceedings may divert the attention of management, even if we prevail. An adverse determination in proceedings of this type

 could subject us to significant liabilities, allow our competitors to market competitive products without a license from us, prohibit us from marketing our products or require us to seek licenses from third parties that may not be available on commercially reasonable terms, if at all.

 If we are deemed an investment company under the Investment Company Act, applicable restrictions could have an adverse effect on our business.

 The Investment Company Act contains substantive legal requirements that regulate the manner in which "investment companies" are permitted to conduct their business activities. We believe that we have conducted our business in a manner that does not result in being characterized as an "investment company" under the Investment Company Act because we are primarily engaged in a non-investment company business. Although a portion of our assets may constitute investments in non-controlled entities, namely our subsidiary, PEC, provided capital to canna-related business clientele, we believe that we are not an investment company as defined by the Investment Company Act. While we intend to conduct our operations such that we will not be deemed an investment company, such a determination would require us to initiate burdensome compliance requirements and comply with restrictions imposed by the Investment Company Act that would limit our activities, including limitations on our capital structure and our ability to transact with affiliates, which would have an adverse effect on our financial condition. To avoid such a determination, we may be required to conduct our business in a manner that does not subject us to the requirements of the Investment Company Act, which could have an adverse effect on our business. For example, we may be required to sell certain of our assets and pay significant taxes upon the sale or transfer of such assets.

 We may be required to recognize impairment charges that could materially affect our results of operations.

 We assess our goodwill and other intangible assets, and our other long-lived assets as and when required by accounting principles generally accepted in the United States ("GAAP") to determine whether they are impaired. If they are impaired, we would record appropriate impairment charges. It is possible that we may be required to record significant impairment charges in the future and, if we do so, our results of operations could be materially adversely affected.

 Risks Related to Ownership of Our Common Stock

 Due to our connection to the cannabis industry, there can be no assurance that our shares of common stock will ever be approved for listing on a national securities exchange.

 Currently, shares of our common stock are traded on the OTC Pink Market and are not listed on any national securities exchange, such as the New York Stock Exchange or the NASDAQ Stock Market. Even if we desire to have our shares listed on a national securities exchange, the fact that our business is associated with the use of cannabis, the legal status of which is uncertain in some states and at the federal level, may make any efforts to become listed on a securities exchange more problematic as we believe national exchanges may be reluctant to list shares of companies whose business is associated with the recreational use of cannabis. While we plan to work with NASDAQ or other exchanges in an attempt to change their views of responsible cannabis related businesses, there can be no assurance that our common stock will ever be listed on NASDAQ or any other national securities exchange. As a result, our common stock may never develop an active trading market which may limit our investors' ability to liquidate their investments or cause our stock price to be particularly volatile.

 Our stock may be traded infrequently and in low volumes, so you may be unable to sell your shares at or near the quoted bid prices if you need to sell your shares.

 Until our common stock is listed on a national securities exchange, our common stock may only trade on one of the OTC Markets (if we are successful in applying to trade on such marketplaces) or on the OTC Pink Market. In those markets, however, the shares of our common stock may trade infrequently and in low volumes, meaning that the number of persons interested in purchasing our common stock at or near bid prices at any given time may be relatively small or non-existent. An investor may find it difficult to obtain accurate quotations as to the market value of our common stock or to sell his or her shares at or near bid prices or at all. In addition, if we fail to meet the criteria set forth in SEC reporting regulations, various requirements would be imposed by law on broker-dealers who sell our securities to persons other than established customers and accredited investors. Consequently, such regulations may

 deter broker-dealers from recommending or selling our common stock, which may further affect the liquidity of our common stock. This would also make it more difficult for us to raise capital.

 There currently is no active public market for our common stock and there can be no assurance that an active public market will ever develop. Failure to develop or maintain a trading market could negatively affect the value of our common stock and make it difficult or impossible for you to sell your shares.

 There is currently no active public market for shares of our common stock, and one may never develop. Our common stock is currently traded on the OTC Pink Market. The OTC Pink Market is a thinly traded market and lacks the liquidity of certain other public markets with which some investors may have more experience. We may not ever be able to satisfy the requirements to be quoted on the OTC Markets or satisfy the listing requirements to be listed on a national securities exchange, which are often more widely traded and liquid markets. Some, but not all, of the factors which may delay or prevent the quotation or listing of our common stock on a more widely-traded and liquid market include the following: our stockholders' equity may be insufficient; the market value of our outstanding securities may be too low; our net income from operations may be too low; our common stock may not be sufficiently widely held; we may not be able to secure market makers for our common stock; and we may fail to meet the rules and requirements mandated by the several exchanges and markets to have our common stock listed. Should we fail to satisfy the initial listing standards of the national exchanges or OTC Markets, or our common stock is otherwise rejected for listing or quotation, and remains traded on the OTC Pink Market, the trading price of our common stock could suffer and the trading market for our common stock may be less liquid, and our common stock price may be subject to increased volatility, making it difficult or impossible to sell shares of our common stock.

 We do not intend to pay dividends in the foreseeable future.

 We do not intend to pay any cash dividends in the foreseeable future. We do not plan on making any cash distributions in the manner of a dividend or otherwise. Our Board of Directors presently intends to follow a policy of retaining earnings, if any.

 Investors may experience dilution of their ownership interests because of the future issuance of additional shares of our common or preferred stock or other securities that are convertible into or exercisable for our common or preferred stock.

 In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our present stockholders. We are authorized to issue an aggregate of 75,000,000 shares of common stock and 10,00,000 shares of "blank check" preferred stock. We may issue additional shares of our common stock or other securities that are convertible into or exercisable for our common stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities for capital raising purposes, or for other business purposes. The future issuance of any such additional shares of our common stock may create downward pressure on the trading price of the common stock. We will need to raise additional capital in the near future to meet our working capital needs, and there can be no assurance that we will not be required to issue additional shares, warrants or other convertible securities in the future in conjunction with these capital raising efforts, including at a price (or exercise or conversion prices) below the price an investor paid for stock.

 Being a public company is expensive and administratively burdensome.

 As a company whose common stock is registered under Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), we are fully subject to the information and reporting requirements of the Exchange Act and other federal securities laws, rules and regulations related thereto, including compliance with the Sarbanes-Oxley Act. Complying with these laws and regulations requires the time and attention of our Board of Directors and management and increases our expenses.

 Among other things, we are required to:

 maintain and evaluate a system of internal controls over financial reporting in compliance with the requirements of Section 404 of the Sarbanes-Oxley Act and the related rules and regulations of the SEC and the Public Company Accounting Oversight Board;

 maintain policies relating to disclosure controls and procedures;

 prepare and distribute periodic reports in compliance with our obligations under federal securities laws;

 institute a more comprehensive compliance function, including corporate governance; and

 involve, to a greater degree, our outside legal counsel and accountants in the above activities.

 The costs of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders are expensive and much greater than that of a privately-held company, and compliance with these rules and regulations may require us to hire additional financial reporting, internal controls and other finance personnel, and will involve a material increase in regulatory, legal and accounting expenses and the attention of management. There can be no assurance that we will be able to comply with the applicable regulations in a timely manner, if at all. In addition, being a public company makes it more expensive for us to obtain director and officer liability insurance. In the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain this coverage.

 Our common stock is subject to the "penny stock" rules of the SEC and the trading market in the securities is limited, which makes transactions in the stock cumbersome and may reduce the value of an investment in the stock.

 Rule 15g-9 under the Exchange Act establishes the definition of a "penny stock," for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person's account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

 In order to approve a person's account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience objectives of the person and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) confirms that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the "penny stock" rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our common stock.

 Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker or dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

 If our stockholders sell substantial amounts of our common stock in the public market, including upon the expiration of any lockup periods or the statutory holding period under Rule 144, or issued upon the conversion of preferred stock, it could create a circumstance commonly referred to as an "overhang" and in anticipation of which the market price of our common stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

 An investment in our securities is speculative and there can be no assurance of any return on any such investment.

 An investment in our securities is speculative and there is no assurance that investors will obtain any return on their investment. Investors will be subject to substantial risks involved in an investment in our Company, including the risk of losing their entire investment.

 Our Articles of Incorporation provide that, unless we consent in writing to the selection of an alternative forum, the Eighth Judicial District Court of Clark County, Nevada will be the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

 Our Articles of Incorporation provide that, unless we consent in writing to the selection of an alternative forum, the Eighth Judicial District Court of Clark County, Nevada will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Nevada Revised Statutes, our Articles of Incorporation or our bylaws. This choice of forum provision does not preclude or contract the scope of exclusive federal or concurrent jurisdiction for any actions brought under the Securities Act or the Exchange Act. Accordingly, our exclusive forum provision will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.

 Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. These exclusive-forum provisions may limit a stockholder's ability to bring a claim in a judicial forum of its choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees.

 If a court were to find the choice of forum provision contained in our Articles of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.

 Item 1B. Unresolved Staff Comments.

 Not applicable.

 Item 2. Description of Property.

 We do not own any real estate or other properties.

 Item 3. Legal Proceedings.

 There are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company.

 Item 4. Mine Safety Disclosure.

 Not applicable.

 Item 5. Market for Common Equity and Related Stockholder Matters.

 Market Information

 There is a limited public market for our common shares. Our common shares are not quoted on the OTC Bulletin Board at this time. Trading in stocks quoted on the OTC Bulletin Board is often thin and is characterized by wide fluctuations in trading prices due to many factors that may be unrelated to a company's operations or business prospects. We cannot assure you that there will be a market in the future for our common stock.

 OTC Bulletin Board securities are not listed or traded on the floor of an organized national or regional stock exchange. Instead, OTC Bulletin Board securities transactions are conducted through a telephone and computer network connecting dealers in stocks. OTC Bulletin Board issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

 As of January 31, 2025, we have had limited trading volume.

 Number of Holders

 As of January 31, 2025, the 19,834,550 issued and outstanding shares of common stock were held by a total of 17 shareholders of record.

 Dividends

 No cash dividends were paid on our shares of common stock during the fiscal year ended January 31, 2025 and 2024.

 Recent Sales of Unregistered Securities

 The Company has 75,000,000, $0.001 par value shares of common stock authorized.

 During the year ended January 31, 2024, the Company issued 1,340,000 shares of common stock for an aggregate gross purchase price of $670,000 (equal to a per share purchase price of $0.50). The issuance paid off debt and the Company received no cash proceeds.

 During the year ended January 31, 2025, the company issued 90,000 shares of common stock and received cash proceeds of $45,000 (equal to a per share purchase price of $0.50) and canceled 1,000,000 shares of common stock.

 There were 19,834,550 shares of common stock issued and outstanding as of January 31, 2025.

 Other Stockholder Matters

 None.

 Item 6. Selected Financial Data.

 Not applicable to smaller reporting companies.

 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

 Results of Operations for the year ended January 31, 2025 and 2024:

 Revenue and cost of goods sold

 For the years ended January 31, 2025 and 2024 the Company generated total revenue of $16,168 and $0. However, as of January 31, 2025, we determined that most of the revenues were uncollectible, and we recognized bad debt expense of $14,204 for the year ended January 31, 2025. Cost of goods sold for the years ended January 31, 2025 and 2024 was $0 and $0.

 Operating expenses

 Total expenses for the years ended January 31, 2025 and 2024 were $31,153 and $59,497. The expenses for the year ended January 31, 2025 consisted of bad debt expense of $14,204, general and administrative costs of $18,821 and a loss on the disposal of the Company's interest in PCI of $14,296. The expenses for the year ended January 31, 2024 bank charges of $2,020; depreciation expense of $460; legal fees of $10,000; audit fees of $27,000; professional fees of $20,017.

 Net Loss

 The net loss for the years ended January 31, 2025 and 2024 was $31,153 and $59,497 respectively.

 Liquidity, and Capital Resources, and Cash Requirements

 During the year ended January 31, 2025, cash used in operations amounted to $45,030. Uses of cash consisted of a net loss of $31,153, an increase in accounts receivable of $14,204 and a decrease in accounts payable of 15,717, which were offset by depreciation expense of $1,840 and bad debt expense of $14,204. During the year ended January 31, 2024, the Company provided $30 of cash in operating activities, consisting of a net loss of $59,497, which was offset by an increase in accounts payable of $16,491, stock-based compensation of $42,576 and depreciation of $460.

 During the years ended January 31, 2025 and 2024 the Company had no investing activities.

 During the years ended January 31, 2025 and 2024, the Company generated $45,001 and $0 of cash in financing activities due to the sale of shares of common stock.

 As of the year ended January 31, 2024, the Company had cash of $30. Furthermore, the Company had an accumulated deficit of $924,574.

 We cannot guarantee that we will manage to sell all the shares required within current offerings. We will attempt to raise the necessary funds to proceed with all phases of our plan of operation.

 Management believes that current trends toward lower capital investment in start-up companies pose the most significant challenge to the Company's success over the next year and in future years. Additionally, the Company will have to meet all the financial disclosure and reporting requirements associated with being a public reporting company. The Company's management will have to spend additional time on policies and procedures to make sure it is compliant with various regulatory requirements, especially that of Section 404 of the Sarbanes-Oxley Act of 2002. This additional corporate governance time required of management could limit the amount of time management has to implement is business plan and impede the speed of its operations. Accordingly, the Company's management has concluded that these conditions raise substantial doubt about our ability to continue as a going concern. There can be no assurance that we will be able to achieve our business plan objectives or be able to achieve or maintain cash-flow-positive operating results. If we are unable to generate adequate funds from operations or raise sufficient additional funds, we may not be able to repay our existing debt, continue to operate our business network, respond to competitive pressures or fund our operations. As a result, we may be required to significantly reduce, reorganize, discontinue or shut down our operations.

 Limited operating history; need for additional capital

 There is no historical financial information about us upon which to base an evaluation of our performance. We are in a start-up stage of operations and have generated minimal revenues since inception. We cannot guarantee that we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products.

 Off-Balance Sheet Arrangements

 The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 Item 7A. Quantitative and Qualitative Disclosure about Market Risk

 Not applicable to smaller reporting companies.

 Item 8. Financial Statements and Supplementary Data.

 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 Page

 Report of Independent Registered Public Accounting Firm

 Consolidated Balance Sheets as of January 31, 2025 and 2024

 Consolidated Statements of Operations for the years ended January 31, 2025 and 2024

 Consolidated Statements of Changes in Shareholders' Equity as of January 31, 2025 and 2024

 Consolidated Statements of Cash Flows for the years ended January 31, 2025 and 2024

 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 To the Board of Directors and Stockholders of Pineapple Express Cannabis Company.

 Opinion on the Financial Statements

 We have audited the accompanying balance sheet of Pineapple Express Cannabis Company (the Company) as of January 31, 2025, and the related statements of income, stockholders' equity, and cash flows for the period ended January 31, 2025, and the related notes (collectively referred to as the financial statements). The financial statements of Pineapple Express Cannabis Company as of January 31, 2024, were audited by other auditors whose report dated May 30, 2024, expressed an unqualified opinion on those statements.

 In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of January 31, 2025, and the results of its operations and its cash flows for the period ended January 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

 Substantial Doubt about the Company's Ability to Continue as a Going Concern

 The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 10 to the financial statements, the Company incurred a net loss of $31,153, working capital deficit of $2,079 an accumulated deficit of $673,646 and holds a cash balance of $0 as at January 31, 2025. These matters raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 10. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

 Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 Critical Audit Matters

 Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there were no critical audit matters

 Aloba, Awomolo & Partners – PCAOB ID # 7275

 /s/ Aloba, Awomolo & Partners

 We have served as the Company's auditor since 2025.

 Ibadan, Nigeria

 May 15, 2025

 Consolidated Balance Sheets

 January 31,

 2025

 January 31,

 2024

 ASSETS

 Current Assets

 Cash and cash equivalents

 $

 -

 $

 Total Current Assets

 -

 Property, plant and equipment, net

 -

 1,840

 TOTAL ASSETS

 $

 -

 $

 1,870

 LIABILITIES AND STOCKHOLDERS' DEFICIT

 Current Liabilities

 Accounts payable and accrued expenses

 2,079

 17,797

 Total Current Liabilities

 2,079

 17,797

 TOTAL LIABILITIES

 2,079

 17,797

 Stockholders' Deficit

 Preferred stock: 10,000,000 shares authorized; $ 0.001 par value.

 0 shares issued and outstanding

 -

 -

 Common stock: 75,000,000 authorized; $ 0.001 par value

 19,834,550 and 20,744,550 shares issued and outstanding, respectively

 19,835

 20,745

 Additional paid-in capital

 651,732

 605,821

 Accumulated deficit

 ( 673,646)

 ( 642,493)

 Total Stockholders' Deficit

 ( 2,079)

 ( 15,927)

 TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

 $

 -

 $

 1,870

 The accompanying notes are an integral part of these consolidated audited financial statements.

 Consolidated Statements of Operations

 For the Years Ended

 January 31,

 2025

 2024

 Revenues

 $

 16,168

 $

 -

 Operating Expenses

 General and administrative expense

 18,821

 59,497

 Bad debt expense

 14,204

 -

 Total operating expenses

 33,025

 59,497

 Net loss from operations

 ( 16,857)

 Other income (expense)

 Loss on sale of ownership interest in PCI

 ( 14,296)

 -

 Net loss before taxes

 $

 $

 Income tax expense

 -

 -

 Net loss

 $

 $

 Basic and diluted loss per share

 $

 ( 0.00)

 $

 ( 0.01)

 Weighted average number of shares outstanding

 19,834,967

 20,301,810

 The accompanying notes are an integral part of these consolidated audited financial statements.

 Consolidated Statement of Stockholders' Deficit

 For the Years Ended January 31, 2025 and 2024

 Shares

 Capital

 Additional

 Paid in

 Capital

 Accumulated

 Deficit

 Total

 Balance, January 31, 2023

 19,004,550

 $

 19,005

 $

 19,641

 $

 ( 582,996)

 $

 ( 544,350)

 Sale of common stock

 1,740,000

 1,740

 586,180,

 -

 587,920

 Net loss

 -

 -

 -

 Balance, January 31, 2024

 20,744,550

 $

 20,745

 $

 605,822

 $

 ( 642,493)

 $

 ( 15,927)

 Sale of common stock

 90,000

 44,911

 -

 45,001

 Cancellation of shares

 ( 1,000,000)

 ( 1,000)

 1,000

 -

 -

 Net loss

 -

 -

 -

 Balance, January 31, 2025

 19,834,550

 $

 19,835

 $

 651,732

 $

 ( 673,646)

 $

 ( 2,079)

 The accompanying notes are an integral part of these consolidated audited financial statements.

 Consolidated Statements of Cash Flows

 For the Years Ended

 January 31,

 2025

 2024

 CASH FLOWS FROM OPERATING ACTIVITIES:

 Net loss

 $

 $

 Adjustment to reconcile net loss to net cash provided in operations:

 Loss on disposition of PCI

 14,269

 -

 Stock compensation

 -

 42,576

 Depreciation

 Bad debt

 14,204

 -

 Change in assets and liabilities:

 Accounts receivable

 ( 14,204)

 -

 Accounts payable

 ( 28,492)

 16,491

 Net Cash provided by (used in) operating activities

 ( 45,031)

 CASH FLOWS FROM FINANCING ACTIVITIES:

 Proceeds from sale of common stock

 45,001

 -

 Net Cash provided by financing activates

 45,001

 -

 Net change in cash and cash equivalents

 ( 30)

 Cash and cash equivalents Beginning of period

 -

 Cash and cash equivalents End of period

 $

 -

 $

 Supplemental cash flow information

 Cash paid for interest

 $

 -

 $

 -

 Cash paid for taxes

 $

 -

 $

 -

 Supplemental Disclosures of Non-cash Investing and Financing Activities

 Assets disposed of in exchange for debt relief

 $

 3,001,495

 $

 -

 Liabilities settled via non-cash disposition

 $

 ( 2,987,199)

 $

 -

 The accompanying notes are an integral part of these consolidated audited financial statements.

 Note 1 - Description of Business

 Pineapple Express Cannabis Company, a Nevada corporation doing business as PINYA XP (the "Company", "Pineapple Express", or "PINYA XP"), operates within the legal cannabis industry and is focused on developing cannabis-related business ventures, including brand development, intellectual property licensing, and technology integration. The Company's common stock is quoted on the OTC Pink Market under the symbol PNXP.

 Historically, the Company has operated through various subsidiaries and strategic partnerships to pursue opportunities in cannabis cultivation, distribution, and consumer-facing products. During the fiscal year ended January 31, 2025, the Company continued to evaluate complementary technology platforms to enhance transparency, authenticity, and safety within the cannabis supply chain.

 Subsequent Acquisition of GROOVY Company, Inc.

 On March 5, 2025, subsequent to the fiscal year end, the Company entered into and consummated a Share Exchange Agreement (the "Agreement") with GROOVY Company, Inc. f/k/a Santo Mining Corp., a Wyoming corporation ("GROOVY"). Pursuant to the terms of the Agreement, the Company exchanges 5,000,000 shares of its common stock for 350,000,000 shares of GROOVY's Series A Preferred Stock, resulting in the Company acquiring a majority voting interest in GROOVY. As of the closing date, GROOVY became a majority-owned subsidiary of the Company.

 GROOVY is a technology company that has developed a centralized, blockchain-based Platform as a Service (PaaS) leveraging Hyperledger Fabric infrastructure to deliver product authentication, intellectual property protection, and traceability solutions to the cannabis industry. The GROOVY platform uses non-fungible token (NFT) technology, including ERC1155, ERC725X, ERC725Y, and ERC735 standards, to assign secure QR-code tags to cannabis products, enabling verifiable transparency from seed to sale.

 Core features of the GROOVY platform include:

 NFT-based QR code authentication to detect and prevent product counterfeiting

 A genetic library (Geno-NFT) for IP registration and automated royalty distribution

 Detailed product provenance and lab test verification

 A consumer-facing mobile application with rewards-based engagement

 Integration tools for growers, retailers, and regulators to access immutable supply chain data

 A marketplace and analytics platform supporting ecosystem-wide insights

 The acquisition of GROOVY represents a strategic expansion into blockchain-based authentication and supply chain management technology. This business combination is expected to enhance the Company's position within the regulated cannabis industry by integrating advanced transparency tools and consumer protection systems into existing and future distribution channels.

 The acquisition is intended to qualify as a reorganization under Section 368 of the Internal Revenue Code of 1986, as amended. The Company has also assumed certain outstanding convertible notes of GROOVY, which, upon conversion, may result in the issuance of additional shares of common stock of the Company.

 The financial results of GROOVY and its subsidiaries will be included in the Company's consolidated financial statements beginning in the first quarter of fiscal year 2026.

 Basis of Presentation

 The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. The Company has a January 31 year end.

 Note 2 - Summary of Significant Accounting Policies

 Use of Estimates

 In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the valuation allowance for deferred tax assets. On a continual basis, management reviews its estimates, utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.

 Cash and Cash Equivalents

 The Company considers all highly liquid investments with maturities of three months or less to be cash equivalents. The Company uses one financial institution for its cash balances and has not maintained cash balances that exceed federally insured limits.

 Revenue Recognition

 The Company recognizes revenue using the following five-step model pursuant to the guidelines established by ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)":

 Identification of the contract, or contracts, with a customer.

 Identification of the performance obligations in the contract.

 Determination of the transaction price.

 Allocation of the transaction price to the performance obligations in the contract; and

 Recognition of revenue when or as, the Company satisfies a performance obligation.

 Fair Value of Financial Instruments

 Under the Fair Value Measurements Topic of the FASB Accounting Standards Codification, the Company bases its fair value on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. It is the Company's policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data and, therefore, are based primarily upon management's own estimates, are often calculated based on current pricing policy, the economic and competitive environment, the characteristics of the asset or liability and other such factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, that could significantly affect the results of current or future value.

 Impairment of long-lived assets

 The Company periodically reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset's estimated fair value and its book value. During the years ended January 31, 2025 and 2024, the Company did not record any impairment losses.

 Stock-Based Compensation

 The Company utilizes the Black-Scholes option pricing model to estimate the fair value of warrant issuances or stock option awards at the date of grant, which requires the input of highly subjective assumptions, including expected volatility and expected life. Changes in these inputs and assumptions can materially affect the measure of estimated fair value of share-based compensation. These assumptions are subjective and generally require significant analysis and judgment to develop. The Company estimates volatility by considering the historical stock volatility. The Company has opted to use the simplified method for estimating the expected term.

 Income Taxes

 The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible.

 The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two step process whereby (1) it determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more likely than not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.

 Based on the Company's history of tax losses, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company's financial statements. The Company believes that its income tax positions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position.

 The Company may in the future become subject to foreign, federal, state and local income taxation though it has not been since inception. The Company is not presently subject to any income tax audit in any taxing jurisdiction.

 Basic Income (Loss) Per Share

 Basic income (loss) per share is calculated by dividing the Company's net income or loss applicable to common shareholders by the weighted average number of common shares during the period. A diluted earnings per share is calculated by dividing the Company's net income available to common shareholders by the diluted weighted average number of shares outstanding during the period. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Loss per share data does not include common stock issuable to holders of convertible securities because their effect is anti-dilutive.

 Recent Accounting Pronouncements

 Management does not believe that any other recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, the Company will adopt those that are applicable under the circumstances.

 The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position or cash flow.

 Note 3 - Income Taxes

 Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated Staff Accounting Bulletin No. 118 regarding the impact of the decreased tax rates of the Tax Cuts & Jobs Act. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. The U.S. federal income tax rate of 21 % is being used.

 The provision for Federal income tax consists of the following at January 31:

 2025

 2024

 Federal income tax benefit attributable to:

 Net operating loss carryforward

 $

 389,564

 $

 358,411

 Less: valuation allowance

 ( 389,564)

 ( 358,411)

 Net deferred tax assets

 $

 -

 $

 -

 The cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows at January 31:

 2025

 2024

 Computed "expected" tax expense (benefit)

 $

 81,808

 $

 ( 75,266)

 Change in valuation allowance

 ( 81,808)

 75,266

 Actual tax expense

 $

 -

 $

 -

 At January 31, 2025, the Company had net operating loss carry forwards of approximately $ 390,000 that may be offset against future taxable income. No tax benefit has been reported in the January 31, 2025 or 2024 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. Management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of January 31, 2025 and 2024.

 ASC Topic 740 provides guidance on the accounting for uncertainty in income taxes recognized in a company's financial statements. Topic 740 requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.

 The Company includes interest and penalties arising from the underpayment of income taxes in the statements of operations in the provision for income taxes. As of January 31, 2025, the Company had no accrued interest or penalties related to uncertain tax positions.

 Note 4 - Stockholders' Equity

 Authorized Capital

 As of January 31, 2025, the Company was authorized to issue up to 85,000,000 shares of capital stock, consisting of 75,000,000 shares of common stock, par value $ 0.001 per share, and 10,000,000 shares of preferred stock, par value $ 0.001 per share. The terms and rights of preferred stock may be designated in one or more series as determined by the Board of Directors in accordance with the Company's Amended and Restated Articles of Incorporation.

 As of January 31, 2025, and January 31, 2024, the Company had 19,834,550 and 20,744,550 shares of common stock issued and outstanding, respectively. During fiscal 2025, 1,000,000 shares of common stock were cancelled and 90,000 shares were sold for cash proceeds of $ 45,001.

 Each share of common stock is entitled to one vote per share on all matters submitted to a vote of the shareholders. Holders of common stock are entitled to receive dividends when and if declared by the Board of Directors. There are no conversion rights, redemption rights, or preemptive rights associated with the common stock.

 Preferred Stock

 As of January 31, 2025, no preferred shares had been issued. The Board of Directors is authorized to establish one or more series of preferred stock and to fix the designations, preferences, and relative, participating, optional or other special rights, and qualifications, limitations or restrictions of each series, including dividend rights, conversion rights, voting rights, redemption terms, and liquidation preferences.

 Subsequent Equity Transactions

 On March 5, 2025, subsequent to the fiscal year end, the Company issued 5,000,000 shares of its common stock pursuant to a Share Exchange Agreement with GROOVY Company, Inc. (f/k/a Santo Mining Corp.), in exchange for 350,000,000 shares of Series A Preferred Stock of GROOVY. As a result of the transaction, the Company acquired a controlling interest in GROOVY, which became a majority-owned subsidiary. See Note 1 - Description of Business and Note 11 - Subsequent Events.

 Note 5 - Fair Value

 The Fair Value Measurements Topic of the FASB Accounting Standards Codification establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

 Level 1: inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the company has the ability to access at the measurement date.

 Level 2: inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

 Level 3: inputs are unobservable inputs for the asset or liability.

 Under the Fair Value Measurements Topic of the FASB Accounting Standards Codification, fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. It is the Company's policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with the fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data and, therefore, are based primarily upon management's own estimates, are often calculated based on current pricing policy, the economic and competitive environment, the characteristics of the asset or liability and other such factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows that could significantly affect the results of current or future value.

 Cash, prepaid expenses, and accounts payable

 In general, carrying amounts approximate fair value because of the short maturity of these instruments.

 Related Party Payable

 The amount payable to a related party is carried at its face value. Based on the small size of the Company, it is impracticable for the Company to estimate the fair value of this liability.

 The Company has no instruments with significant off balance sheet risk.

 Note 6 - Commitments and Contingencies

 Contingencies

 We face risks related to health epidemics and other outbreaks, which could significantly disrupt the Company's operations. The outbreak of pandemics and epidemics could materially and adversely affect the Company's business. The extent to which a pandemic or other health outbreak impacts the Company's results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of a virus and the actions to contain it or treat its impact, among others. Pandemics can also result in social, economic, and labor instability which may adversely impact the Company's business.

 Litigation

 The Company accrues loss contingencies associated with outstanding litigation, claims and assessments for which management has determined it is probable that a loss contingency exists, and the amount of loss can be reasonably estimated. Costs for professional services associated with litigation claims are expensed as incurred. As of January 31, 2025 and 2024, the Company has not accrued or incurred any amounts for litigation matters.

 Note 7 - Net Income (Loss) Per Common Share

 Net income (loss) per share is calculated in accordance with FASB ASC 260, "Earnings Per Share." The weighted-average number of common shares outstanding during each year is used to compute basic earnings or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised.

 Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding at January 31, 2025, and 2024, respectively. As of January 31, 2025, and 2024, the Company had no dilutive common shares.

 Note 8 - Related Party Transactions

 Sale of Interest in Pineapple Consolidated, Inc.

 On January 31, 2025, the Company entered into a Stock Purchase Agreement with Mr. Matthew Feinstein, the Company's then-President, Chief Executive Officer, Treasurer, and a member of the Board of Directors. Pursuant to the agreement, the Company sold its remaining 25% ownership interest in Pineapple Consolidated, Inc. ("PCI") to Mr. Feinstein in exchange for a $ 3,000,000 reduction in the outstanding principal amount of a promissory note previously issued by PCI to the Company. As a result of the transaction, the Company no longer retains any ownership interest in PCI.

 Change in Control and Executive Transition

 On January 30, 2025, Mr. Matthew Feinstein and Mr. Shawn Credle collectively sold an aggregate of 16,000,000 shares of the Company's common stock to Mr. Franjose "Frank" Yglesias for $ 335,000 in cash pursuant to a Share Purchase Agreement. The transaction resulted in a change in control of the Company.

 Following this change in control, on February 12, 2025, Mr. Feinstein resigned from all positions with the Company, including as Chief Executive Officer, President, Director, and Chairman of the Board. On the same date, the Board of Directors appointed Mr. Yglesias as the new Chief Executive Officer, President, Director, and Chairman of the Board.

 Mr. Yglesias is also the Chief Executive Officer and controlling shareholder of GROOVY Company, Inc. ("GROOVY"), which was acquired by the Company on March 5, 2025, as described in Note 1 – Description of Business. Accordingly, Mr. Yglesias is considered a related party with respect to transactions between the Company and GROOVY following the change in control.

 Acquisition of GROOVY Company, Inc.

 On March 5, 2025, subsequent to the fiscal year end, the Company entered into a Share Exchange Agreement with GROOVY Company, Inc. Under the agreement, the Company agreed to issue 5,000,000 shares of common stock in exchange for 350,000,000 shares of Series A Preferred Stock of GROOVY, resulting in the Company obtaining majority voting control of GROOVY. In connection with the acquisition, the Company also assumed certain outstanding convertible notes of GROOVY, which may convert into common shares of the Company in future periods.

 Given Mr. Yglesias's dual role as CEO of both companies at the time of the transaction, this transaction is considered a related party transaction.

 Executive Compensation and Other Transactions

 During the fiscal years ended January 31, 2025 and 2024, certain officers and directors, including Mr. Feinstein, provided services to the Company. Other than the transactions described above, there were no material cash or equity compensation arrangements with related parties, and no other transactions required to be disclosed.

 Note 9 - Sale of Investment in Pineapple Consolidated, Inc.

 On January 31, 2025, the Company entered into a Stock Purchase Agreement with Matthew Feinstein, the Company's President, Chief Executive Officer, Treasurer, and Director, pursuant to which the Company sold its remaining 25% equity interest in Pineapple Consolidated, Inc. ("PCI") to Mr. Feinstein. In consideration for the transfer of these shares, the Company agreed to a $3,000,000 reduction in the outstanding principal amount due to the Company under a previously issued $3,000,000 promissory note from PCI.

 In connection with the disposition, the Company also transferred certain related assets and liabilities associated with PCI. The assets disposed of consisted of equipment with a carrying value of $ 1,495 and an intangible asset with a carrying value of $ 3,000,000, representing the Company's recorded value of its investment in PCI. In exchange, the Company extinguished $ 2,966,714 outstanding notes payable and $ 20,485 of accounts payable and accrued liabilities.

 No cash was exchanged in the transaction. The disposition was accounted for as a non-cash investing and financing activity and resulted in a loss of $ 14,296, calculated as follows:

 Description

 Amount

 Total assets disposed

 $ 3,001,495

 Less: Total liabilities settled

 ( 2,987,199)

 Loss on disposition

 $ 14,296

 The loss has been recorded in other expenses in the consolidated statement of operations for the year ended January 31, 2025.

 This transaction was considered a related party transaction, as Mr. Feinstein was an officer and director of the Company.

 Note 10 - Going Concern Matters and Realization of Assets

 The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of January 31, 2025, the Company had limited cash resources, an accumulated deficit, and has incurred recurring losses from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the issuance of these financial statements.

 Management's plans to address these matters include:

 Acquiring and integrating GROOVY Company, Inc., which has developed a blockchain-based supply chain authentication platform aimed at creating strategic growth opportunities in the cannabis technology sector;

 Pursuing additional financing, through the issuance of equity or debt securities, strategic partnerships, or other capital-raising transactions;

 Business realignments to improve operational efficiency and extend cash runway;

 Commercializing blockchain and authentication technology in existing cannabis distribution networks.

 There is no assurance, however, that management will be successful in achieving these plans or that any such funding will be available on acceptable terms or at all. If the Company is unable to generate sufficient revenues or secure adequate financing, it may be required to delay or curtail its business activities, scale back operations, or seek protection under applicable bankruptcy laws.

 Accordingly, the Company's management has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the issuance date of these financial statements. There can be no assurance that the Company will be able to achieve its business plan objectives or be able to achieve or maintain cash-flow-positive operating results. If the Company is unable to generate adequate funds from operations or raise sufficient additional funds, the Company may not be able to repay its existing debt, continue to operate its business network, respond to competitive pressures or fund its operations. As a result, the Company may be required to significantly reduce, reorganize, discontinue or shut down its operations. The financial statements do not include any adjustments that might result from this uncertainty.

 Note 11 - Subsequent Events

 On March 5, 2025, Pineapple Express Cannabis Company (the "Company") entered into and closed a Share Exchange Agreement (the "Agreement") with GROOVY Company, Inc. f/k/a Santo Mining Corp., a Wyoming corporation ("GROOVY"), pursuant to which the Company acquired a controlling interest in GROOVY. Under the terms of the Agreement, the Company agreed to exchange 5,000,000 shares of its common stock for 350,000,000 shares of Series A Preferred Stock of GROOVY. The Series A Preferred Stock entitles the Company to over 51 % of the total voting power of GROOVY, resulting in GROOVY becoming a majority-owned subsidiary of the Company effective upon closing.

 GROOVY is a technology company that has developed a blockchain-based Platform as a Service (PaaS) designed for transparency, authenticity verification, and supply chain management in the cannabis industry, utilizing NFT-based QR code systems and smart contract infrastructure via Hyperledger Fabric. The platform also offers a genetic library, automated royalty distribution mechanisms, user rewards programs, and data analytics tools.

 As part of the transaction, the Company also agreed to assume certain outstanding convertible promissory notes of GROOVY. These notes, which amounted to $ 3,678,753 as of December 31, 2024, are expected to convert into shares of common stock of the Company under their existing terms. The total number of shares to be issued upon conversion of these notes has not been finalized as of the date of this filing.

 The transaction is intended to qualify as a tax-deferred reorganization under Section 368 of the Internal Revenue Code of 1986, as amended, or such other tax-free reorganization or restructuring provisions as may be applicable.

 The Share Exchange Agreement contains customary representations, warranties, and covenants. Closing conditions included, among other things, satisfactory due diligence, receipt of necessary approvals, and the absence of a material adverse effect.

 In connection with the acquisition, the Company and GROOVY also agreed to changes in the composition of the Company's board of directors, to take effect following a mutually agreed transition period.

 GROOVY has the following subsidiaries, which became indirect subsidiaries of the Company upon the closing of the transaction:

 BlackFlamingo Ventures, LLC

 Cathay International, LLC

 Santo Blockchain Labs Corporation

 Santo Blockchain Labs of Colombia S.A.S.

 In March 2025 and in May 2025, the Company issued 500,000 and 1,000,000 shares of its common stock, respectively, for debt conversions of an aggregate of $ 150,000, from its GROOVY subsidiary.

 The company has evaluated all subsequent events. There were no other material subsequent events that required recognition or additional disclosure in these financial statements.

 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 None.

 Item 9A. Controls and Procedures

 Disclosure Controls and Procedures.

 The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to ensure that information required to be disclosed in the Company's Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to the Company's management, as appropriate, to allow timely decisions regarding required disclosure.

 The Company's management, with the participation of our principal executive and principal financial officer evaluated the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, our principal executive and principal financial officer concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures were not effective.

 Management's Report on Internal Controls over Financial Disclosure Controls and Procedures

 Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)). The Company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the Company's internal control over financial reporting as of January 31, 2025 using the criteria established in "Internal Control - Integrated Framework" issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

 A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of January 31, 2025, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.

 1. We do not have an Audit Committee – While not being legally obligated to have an audit committee, it is the management's view that such a committee, including a financial expert member, is an utmost important entity level control over the Company's financial statement. Currently the Board of Directors acts in the capacity of the Audit Committee and does not include a member that is considered to be independent of management to provide the necessary oversight over management's activities.

 2. We did not maintain appropriate cash controls – As of January 31, 2025, the Company has not maintained sufficient internal controls over financial reporting for the cash process, including failure to segregate cash handling and accounting functions, and did not require dual signature on the Company's bank accounts. Alternatively, the effects of poor cash controls were mitigated by the fact that the Company had limited transactions in their bank accounts.

 3. We did not implement appropriate information technology controls – As of January 31, 2025, the Company retains copies of all financial data and material agreements; however, there is no formal procedure or evidence of normal backup of the Company's data or off-site storage of data in the event of theft, misplacement, or loss due to unmitigated factors.

 Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company's internal controls.

 As a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control over financial reporting as of January 31, 2025 based on criteria established in Internal Control- Integrated Framework issued by COSO.

 System of Internal Control over Financial Reporting

 Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of January 31, 2025. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms.

 Changes in Internal Control over Financial Reporting

 There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As described above, the Company has concluded that the internal control over financial reporting is ineffective in 2023 because of the material weakness identified by our independent auditor.

 Item 9B. Other Information

 None.

 Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

 Not Applicable.

 Item 10. Directors, Executive Officers and Corporate Governance

 As of January 31, 2025, the Company's sole executive officer and director was Matthew Feinstein.

 On February 12, 2025, Matthew Feinstein resigned from all positions with the Company, including as Chief Executive Officer, President, Director, and Chairman of the Board. His resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. A copy of Mr. Feinstein's resignation letter is filed as Exhibit 10.6 to this Form 10-K and was previously disclosed in a Current Report on Form 8-K filed with the SEC on February 19, 2025.

 On the same date, the Board of Directors appointed Franjose "Frank" Yglesias to serve as Chief Executive Officer, President, Director, and Chairman of the Board. Mr. Yglesias currently serves in these roles.

 As of January 31, 2025, the name, age and titles of our executive officer and director are as follows.

 Name and Address of Executive

 Officer and/or Director

 Age

 Position

 Matthew Feinstein,

 12301 Wilshire Blvd. #302,

 LA CA 90025

 President, Treasurer, Secretary and Director

 (Principal Executive, Financial and Accounting Officer)

 During the past ten years, Matthew Feinstein has not been the subject to any of the following events:

 1. Any bankruptcy petition filed by or against any business of which Matthew Feinstein was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time.

 2. Any conviction in a criminal proceeding or being subject to a pending criminal proceeding.

 3. An order, judgment, or decree, not subsequently reversed, suspended or vacated, or any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting Mr. Feinstein's involvement in any type of business, securities or banking activities.

 4. Found by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission or the Commodity Future Trading Commission to violate a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

 5. Was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right to engage in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity;

 6. Was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

 7. Was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

 i. Any Federal or State securities or commodities law or regulation; or

 ii. Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

 iii. Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

 8. Was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a) (26) of the Exchange Act (15 U.S.C. 78c(a) (26))), any registered entity (as defined in Section 1(a) (29) of the Commodity Exchange Act (7 U.S.C. 1(a) (29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 TERM OF OFFICE

 Our director is appointed to hold office until the next annual meeting of our stockholders or until her respective successor is elected and qualified, or until he resigns or is removed in accordance with the provisions of the Nevada Revised Statues.

 DIRECTOR INDEPENDENCE

 Mr. Feinstein does not qualify as an independent director in accordance with the published listing requirements of the NASDAQ Global Market (the Company has no plans to list on the NASDAQ Global Market). The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our board of directors has not made a subjective determination as to Matthew Feinstein that no relationships exist which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our board of directors made these determinations, our board of directors would have reviewed and discussed information provided by directors and us regarding our director's business and personal activities and relationships as they may relate to us and our management

 Item 11. Executive Compensation

 MANAGEMENT COMPENSATION

 The following tables set forth certain information about compensation paid, earned or accrued for services by our Executive Officer as of January 31, 2025 and 2024.

 Summary Compensation Table

 Name and Principal

 Position

 Year

 Salary

 ($)

 Bonus

 ($)

 Stock

 Awards

 ($)

 Option

 Awards

 ($)

 Non-Equity

 Incentive Plan

 ($)

 Nonqualified

 Deferred

 ($)

 All Other

 ($)

 Total

 ($)

 Matthew Feinstein,

 2025

 President and Treasurer

 2024

 There are no current employment agreements between the company and its officer.

 Matthew Feinstein devoted all his time needed for planning and organizing activities to manage the affairs of the Company. He has agreed to work with no remuneration until such time as the company receives sufficient revenues necessary to provide management salaries. At this time, we cannot accurately estimate when sufficient revenues will occur to implement this compensation, or what the amount of the compensation will be. There is no annuity, pension or retirement benefit proposed to be paid to the officer or director or employees in the event of retirement at normal retirement date pursuant to any presently existing plan provided or contributed to by the company or any of its subsidiaries, if any.

 Director Compensation

 The following table sets forth director compensation as of January 31, 2025 and 2024:

 Name

 Fees

 Earned

 or Paid

 in Cash

 ($)

 Stock

 Awards

 ($)

 Option

 Awards

 ($)

 Non-Equity

 Incentive

 Plan

 ($)

 Nonqualified

 Deferred

 Earnings

 ($)

 All Other

 ($)

 Total

 ($)

 Matthew Feinstein

 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 The following table sets forth certain information concerning the number of shares of our common stock, owned beneficially as of January 31, 2025 by: (i) each person (including any group), known to us to own more than five percent (5%) of any class of our voting securities, (ii) our director, and or (iii) our officer. Unless otherwise indicated, the stockholder listed possesses sole voting and investment power with respect to the shares shown.

 Title of Class

 Name and Address of

 Beneficial Owner

 Amount and Nature of

 Beneficial Ownership

 Percentage

 Matthew Feinstein

 15,000,000 shares of common stock (direct)

 75.6%

 Shawn Credle

 1,000,000 shares of common stock (direct)

 5.0%

 Marco Rullo

 1,000,000 shares of common stock (direct)

 5.0%

 (1) A beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the number of shares beneficially owned by such person (and only such person) by reason of these acquisition rights.

 Item 13. Certain Relationships and Related Transactions, and Director Independence

 Until his resignation on February 12, 2025, Matthew Feinstein served as our officer, director, control person, and promoter. His resignation was disclosed in a Current Report on Form 8-K filed with the SEC on February 19, 2025. He received no compensation for the placement of any offerings from the Company.

 Item 14. Principal Accountant Fees and Services

 During fiscal year ended January 31, 2024, we incurred approximately $31,000 in fees to our principal independent accountants for professional services rendered for the reviews of our financial statements for the quarters ended April 30, 2023, July 31, 2023 and October 31, 2023. In fiscal year ended January 31, 2025, we incurred an aggregate of $5,000 in fees to our principal independent accountants.

 Item 15. Exhibits

 The following exhibits are included as part of this report by reference:

 Number

 Description

 2.1

 Share Exchange Agreement, dated as of December 18, 2022, among the Company, Pineapple Consolidated, Inc. and the stockholders of Consolidated, Inc. (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K, filed with the SEC on January 19, 2023).

 2.2

 Resignation, Separation and Release Agreement dated December 18, 2022 (incorporated by reference to Exhibit 2.2 to the Company's Current Report on Form 8-K, filed with the SEC on January 19, 2023).

 3.1

 Restated Articles of Incorporation as filed with the State of Nevada on January 5, 2023 (incorporated by reference to Exhibit 3.1(i) to the Company's Current Report on Form 8-K, filed with the SEC on January 19, 2023).

 10.1

 Promissory Note, dated December 18, 2022, from the Company to PCI (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on January 19, 2023).

 10.2

 Revenue Sharing Agreement and Promissory Note, by and between Ananas Growth Ventures, Pineapple Express Cannabis Company, and Pineapple Consolidated, Inc., dated as of June 10, 2024 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on June 11, 2024).

 10.3

 Stock Purchase Agreement between Matthew Feinstein, Pineapple Express Cannabis Company, and Pineapple Consolidated, Inc., dated as of August 9, 2024 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on August 13, 2024).

 10.4

 Stock Purchase Agreement between Matthew Feinstein, Pineapple Express Cannabis Company, and Pineapple Consolidated, Inc., dated as of January 31, 2025 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on February 7, 2025).

 10.5

 Stock Purchase Agreement, (incorporated by reference to Exhibit 5.1 to the Company's Current Report on Form 8-K, filed with the SEC on February 19, 2025).

 10.6

 Resignation letter of Matthew Feinstein, dated February 12, 2025 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K, filed with the SEC on February 19, 2025).

 10.7

 Share Exchange Agreement, (incorporated by reference to Exhibit 5.1 to the Company's Current Report on Form 8-K, filed with the SEC on March 11, 2025)

 19.1

 Insider Trader Policy, adopted by the registrant on May 7, 2024.

 31.1 *

 Certification of Chief Executive Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a).

 31.2 *

 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 32.1 *

 Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.

 32.2 *

 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 101. INS

 101. SCH

 101. CAL

 101. DEF

 101. LAB

 101. PRE

 * Filed herewith.

 SIGNATURES

 Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in Los Angeles on May 15, 2025.

 By:

 /s/ Franjose Yglesias

 Name:

 Franjose Yglesias

 Title:

 Chief Executive Officer